



## Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

**Publisher's Disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

*All legal disclaimers applicable to the journal apply to this production process as well.*

Monaldi Arch Chest Dis 2024 [Online ahead of print]

*To cite this Article:*

Benmaamar S, Es-sabbahi B, Taghyiollah Haiba M, et al. **Economic burden of chronic obstructive pulmonary disease in Morocco: a cost of illness study.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2024.2745

 ©The Author(s), 2024  
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



**Economic burden of chronic obstructive pulmonary disease in Morocco:  
a cost of illness study**

Soumaya Benmaamar,<sup>1</sup> Btissame Es-sabbahi,<sup>2</sup> Mohammed Taghyiollah Haiba,<sup>2</sup>  
Mohamed Omari,<sup>1</sup> Ibtissam El Harch,<sup>1</sup> Mohammed Youbi,<sup>3</sup> Latifa Belakhhel,<sup>3</sup>  
Loubna Abousselham,<sup>3</sup> Hafid Hachri,<sup>4</sup> Imane El Menchawyi,<sup>4</sup>  
Samira EL Fakir,<sup>1</sup> Mohammed Chakib Benjelloun,<sup>2</sup> Nabil Tachfouti<sup>1</sup>

<sup>1</sup>Department of Epidemiology, Clinical Research and Community Health, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez; <sup>2</sup>Department of Pulmonology, Hassan II University Hospital of Fez; <sup>3</sup>Department of Epidemiology and Disease Control, Ministry of Health and Social Protection, Rabat; <sup>4</sup>World Health Organization Country Office, Morocco

**Correspondence:** Soumaya Benmaamar, Laboratory of Epidemiology, Clinical Research and Community Health, Faculty of Medicine and Pharmacy, Km 2.2 Route Sidi Harazem Fez, Morocco.

E-mail: [soumaya.benmaamar@usmba.ac.ma](mailto:soumaya.benmaamar@usmba.ac.ma)

**Contributions:** all the authors made a substantive intellectual contribution. All the authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

**Conflict of interest:** the authors declare that they have no competing interest.

**Ethics approval and consent to participate:** the study was approved by the Ethics Committee of the Ibn Sina University Hospital in October 2021. Reference: 57/21.

**Funding:** this work was supporting by World health Organization consultant contract 202755314.

**Availability of data and materials:** all data generated or analyzed during this study are included in this published article.

**Acknowledgments:** the research team sincerely thanks Pr. Amara Bouchra and Pr. Mounia Serraj from the Department of Pulmonology, Hassan II University Hospital of Fez and Dr. Nada Bennani Mchita and Dr. Jinane Iklafe from the Directorate of Epidemiology and Disease Control, Ministry of Health, for their help in the implementation of this work.

## **Abstract**

Chronic obstructive pulmonary disease (COPD) carries an important economic burden worldwide. However, the cost of this disease in Morocco is not well explored. This study aimed to estimate the economic cost associated with COPD in Morocco and identify its determinants.

A cost of illness, prevalence-based study using a bottom-up approach method, including COPD patients, was carried out in 2021-2022. The cost was estimated from a societal perspective, and the time horizon was 1 year. Data collection was performed using a questionnaire including socio-demographic, clinical data, and utilization of health care resources in 2019: hospitalization, medical tests, medications, and medical visits.

Direct health cost (DHC) was estimated by multiplying the use of health services by the official prices (unit costs) published by the National Agency for Health Insurance. The indirect cost (IC) represented by labor productivity losses was calculated using the human capital method. Costs were compared according to different socio-demographic and clinical factors. We included 159 patients; 82.4% were men, 80.4% were current or former smokers, and 78.7% were categorized as "high-risk" groups (grades C–D).

The DHC was estimated at \$1816.6 per patient per year. Pharmaceutical and hospitalization costs represented the highest part of the total DHC (42.5% and 22.1%, respectively). The IC was estimated at \$709.5±1081.3 per patient per year.

DHC increased with increasing disease severity and with the number of severe exacerbations ( $p < 0.001$ ). Current and former smokers were more costly to the healthcare

system than nonsmokers ( $p=0.029$ ). IC also increased with the number of severe exacerbations ( $p=0.003$ ).

In this study, we showed that COPD in Morocco generates important costs for the health system, mainly related to smoking and the severity of the disease. It is therefore important to strengthen tobacco control measures in our country.

**Key words:** COPD, cost, severity of COPD, tobacco, Morocco.

## **Introduction**

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease defined by permanent obstruction of the airways. It is an important cause of morbidity and mortality. In 2019, 212.3 million prevalent cases of COPD were reported worldwide [1]. The incidence rate of COPD was 200.5 per 100,000 [2]. More than 3 million people died of COPD in 2019 [1], and COPD was the 3<sup>rd</sup> leading cause of death worldwide [2]. COPD is a chronic disease requiring lifelong clinical care and management, which consume significant health-care resources (hospitalizations, medical visits, medications, medical tests), thus involving important direct cost incurred by individuals, families, governments, and insurers. Studies evaluating direct COPD costs have generated widely variable estimates across countries. In an international survey conducted in 12 countries, the annual direct cost of COPD per patient ranged from \$504 in South Korea to \$9,981 in the USA [3].

COPD is also associated with a substantial economic burden in terms of indirect costs incurred by lost working days. According to the Centers for Disease Control and Prevention, total absenteeism costs were \$3.9 billion in 2010, with an estimated 16.4 million days of work lost due to COPD [4].

Various factors are associated with the cost of COPD management. Data from the literature [5] have shown that there is a direct relationship between the severity of COPD and the cost of care. Indeed, the cost increases as COPD severity increases.

The chronic and progressive course of chronic obstructive pulmonary disease (COPD) is often marked by “exacerbations”, and their management is associated with a high

economic cost due to hospitalization and intense medical treatment to manage symptoms, which has been documented in a number of studies [5].

Smoking is seen as the most important risk of COPD. The results of the studies showed that smoking is associated with higher health care utilization and cost [6,7]. Smoking was associated with additional annual costs of €743 per current smoker and €1,108 per former smoker [8]. In fact, smoking will lead to higher medical costs and a greater loss of productivity in COPD patients who smoke.

In low- and middle-income countries (LMICs), most of the people suffering from this disease live [9,10] and related deaths account for 90% of deaths worldwide [11]. The results of the "BREATH study" showed that the prevalence of COPD in the MENA region was 3.6%, ranging from 1.9% in the UAE to 6.1% in Syria [12].

In Morocco, the BOLD study reports the prevalence of COPD at 12.6% [13], and mortality related to respiratory diseases, including COPD, represents 6% of all deaths [14]. High morbidity and mortality are also accompanied by an important socioeconomic burden [5,15]. However, research on the cost of COPD management is limited for most of these countries, including Morocco.

The objective of this study was to estimate the economic cost associated with COPD in Morocco and to identify its determinants.

## **Materials and Methods**

### ***Study design and population***

A cost of illness study [16], was carried out in 2021-2022 at the Pulmonology Department of Hassan II University Hospital of Fez. Patients aged 40 years or older diagnosed with COPD at least one year before 2019 and whose electronic medical records were available for 2019 were included. The diagnosis of COPD was performed according to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018 [17]. The choice of the year 2019 for data collection is justified by the propagation of the COVID-19 pandemic during 2020 and 2021, which has influenced the management and follow-up of patients.

### ***Data collection***

Data collection was carried out using a standardized structured questionnaire, including: sociodemographic and socioeconomic data (age, sex, profession and medical insurance).

Risk factors: exposure to tobacco or household smoke.

Clinical data: year of COPD diagnosis, severity of the disease according to GOLD classification, and number of severe exacerbations per year.

COPD exacerbation is defined as "an acute worsening of respiratory symptoms that results in additional therapy" [17]. It's classified as mild (treated with short acting bronchodilators (SABDs) only), moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or severe (patient requires hospitalization or visits the emergency room) [17].

Regarding severity, according to guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [17], COPD patients were classified into four groups: low risk groups (A, B), and high risk groups (C, D).

Utilization of health care resources in 2019: medical visits to the pulmonology specialist. Medication linked to the respiratory system: short-acting  $\beta$ 2 agonist (SABA), long-acting muscarinic antagonist (LAMA), long-acting  $\beta$ 2 agonist (LABA), inhaled corticosteroid (ICS), and antibiotics.

Vaccines: flu or pneumococcal.

Medical tests: laboratory tests, functional tests (arterial gas-analysis, spirometry, walk test), and imaging chest tests (X-ray and/or computed tomography).

Hospital admissions: in the emergency room, intensive care unit or in pulmonology department and, length of stay at the hospital.

Home long-term oxygen therapy (LTOT) and noninvasive home ventilation (NIV).

### ***Measuring patient costs***

Costs were estimated from a societal perspective that includes all direct medical costs and lost productivity for all members of a given society [16]. It is the most complete and recommended for cost of illness studies. Costs were calculated using a prevalence-based approach that considers all existing cases during a given year and all health care resources and lost productivity used within that year [18]. The time horizon adopted in the study was one year.

In our study, we estimated both the direct and indirect costs of the COPD. Direct costs refer to the expenses directly associated with the diagnosis, treatment, and management of the disease [16]. Indirect costs encompass the financial impact of the illness on productivity due to absenteeism, reduced work productivity [16].

For estimating the direct cost, this study adopted a bottom-up approach that consists of measuring and quantifying the health inputs used and then estimating the unit costs of these inputs. Total costs are calculated by multiplying the unit costs by the quantities used [16]. We first listed the different direct health resources used for each patient during the year 2019. Then, DHC were estimated by multiplying the use of health services by the official prices (unit costs) published by the national agency for health insurance for university hospitals (CHU) [19]. Concerning the cost of home oxygen therapy and noninvasive home ventilation, it was calculated based on prices reimbursed by the national agency for health insurance [20]. Regarding the costs of medication consumed by the patient, they were extracted directly from the Reimbursable Drug Guideline developed by the health insurance agency [21]. Finally, all costs were converted from Moroccan Dirhams (MAD) to USD (\$) (31 December, 2019 value) [22].

Indirect cost represented by labor productivity lost by the patient was measured using the human capital method [23,24]. This method is based on the equivalence between the value of lost productivity and the associated annual earnings for obtaining this production.

Labor productivity losses for each patient was included days of absenteeism from work due to medical visits, medical tests, and hospitalizations. IC was calculated by multiplying the annual work loss by the annual average income per capita and by the employment rate, according to the formula below:

$$IC = \frac{N \times ExGDP}{365}$$

IC: indirect cost

N: Average number of days of lost productivity per year

E: Employment rate of working-age population: 0.922 (men) and 0.865 (women) \*

GDP: Gross domestic product per capita: 3230 US\$ in 2019\*\*

\*High planning commission of Morocco; \*\*World Bank

The estimation of IC was only considered in patients of working age based on effective retirement age in Morocco.

The cost per patient per year refers to the average cost of COPD per patient per year.

### ***Statistical analysis***

Descriptive statistics were used to describe the main variable, which is the direct medical cost and its components, as well as the socio-demographic and clinical characteristics of participants: mean and standard deviations were calculated for all continuous variables, and frequencies were calculated for categorical variables. The normality of the cost variable was tested by the Kolmogorov- Smirnov test. Cost comparison was carried out by smoking, sex, COPD severity group, and by frequency of exacerbation using Mann-Whitney test, due to non-normality of cost variables. The linear regression was used to assess the association between cost and age.

Statistical significance was set at 0.05. The statistical analyses were performed using IBM SPSS Statistics V28.0.

## **Results**

### ***Description of population***

Out of 159 patients, (82.4%) were men. The mean age was 68.7(9.7) years. Almost half of patients were employed (49.6%), and (24.2%) had medical insurance.

The majority of COPD patients were current smokers or ex-smokers (80.4%) and (15.8%) were exposed to household smoke.

According to the GOLD classification, 78.7 % were categorized as “high-risk” groups (grades C–D), and 40.9% had one or more exacerbations per year. The demographic and clinical characteristics of COPD patients, are presented in Table 1.

### ***Utilization of health care resources***

The average number of pulmonology visits was  $3.7 \pm 1.7$  per patient per year and the mean day in hospitalizations was  $0.7 \pm 1.15$  per patient per year. The mean day in the hospital was  $13.01 \pm 11.48$ . The most frequently performed medical tests were spirometry ( $2.21 \pm 2.06$ ), walk test ( $1.52 \pm 1.36$ ), arterial gas analysis ( $1.45 \pm 1.45$ ) and, chest X-ray



(1.32±1.66). Overall, 20.1% of the patients used home oxygen therapy and 5.7% used noninvasive home ventilation.

Table 2 shows the description of the utilization of different health care resources by COPD patients in 2019.

### **Cost estimations**

#### *Direct cost*

The mean annual direct cost of COPD was estimated at \$1816.6 ±1582.7 per patient (Table 3). The pharmaceutical treatment cost of COPD was estimated at \$ 773.3±470.7 per patient per year. It represented 42.5% of the total DHC. The cost of hospital admissions accounted for 22.1% of DHC and was estimated at \$ 402±807. The mean cost for medical tests and medical visits represented, respectively, 15.4 % and 1.7% of total DHC. The cost of the vaccines (flu and pneumococcal) constituted 0.6% of DHC. The cost of home oxygen therapy and noninvasive ventilation constituted 17.7% of DHC; it was estimated at \$321.3 (Table 3).

The annual direct cost for patients of “high-risk” groups (GOLD groups C–D) was significantly higher compared to the cost for patients of “low-risk” groups (GOLD groups A–B) (\$791.7±522.8 vs for \$2080.6±1618.6,  $p<0.001$ ).

The analysis also showed statistically significant differences between DHC and frequency of severe exacerbations ( $p<0.001$ ). The cost is approximately threefold higher among patients with  $\geq 1$  per year severe exacerbations (\$2983.4±1812.8 vs \$1009.8± 620.3).

Former smokers and current smokers were more costly to the healthcare system than nonsmokers ( $P=0.029$ ).

There was no significant association between costs and age and sex.

Table 4 shows different factors associated with direct cost in COPD patients.

#### *Lost work of productivity and indirect cost*

The average days of lost productivity was 88 days. The mean annual indirect cost of COPD was estimated at \$709.5 ± 1081.3 per patient. It was 2.5 times higher among patients with  $\geq 1$  per year severe exacerbations (\$1181.5±1334.8 vs \$473.9± 862.7) ( $p=0.003$ ). No significant association was observed between indirect cost and tobacco smoking and frequency of severe exacerbations.

There was no significant association between costs and age and sex. Table 4 shows different factors associated with indirect costs in COPD patients.

### **Discussion and Conclusions**

This study is the first to our knowledge to estimate the economic cost of COPD in Morocco. The results showed that the direct and indirect cost was estimated at \$1816.6 and \$709.5 respectively.

The annual per patient direct medical cost was reported as \$10367 in the USA, while in Asian countries, such as Iran, Korea, and Singapore, the annual per patient direct medical cost was reported as \$1544, \$3077, and \$2335 respectively. In Europe, it's varies from \$1889 in Spain to \$11787 in Norway [25]. The variability of DHC between countries is due to differences in the unit prices of different healthcare services, variation in care practices, and the variability of the COPD patients included in each study in terms of disease severity and the different methods used for evaluating the cost.

In European countries, the cost of work productivity loss varied between approximately \$300 and \$5000 [25]. It was estimated at \$20844, \$5243, \$5467 in the USA, Japan, and South korea, respectively [3]. The variability observed in the indirect cost between countries is related to differences in the approach used.

Our results indicated that the proportion of DHC corresponding to pharmacological costs was (42.5%). This result is similar to the one found in a Spanish study (44.5%) [26]. However, the cost of medications used in the management of COPD accounted for between 4 and 33% of total DHC across countries [3]. This disparity in drug costs in various countries is due to variations in prescribing practices. The higher percentage of medication cost in our study may be explained by the fact that our survey was conducted in a tertiary center, where most patients (78%) had advanced COPD (C-D). The review of Rehman et al. [27] reported that medication cost was higher for patients attending tertiary care facilities than for patients attending primary care facilities.

The cost of hospitalization constituted (22.1 %) of total direct costs. This proportion is similar to that found in Spain (23.1%) [26], in Russia (22%), in the Netherlands (20%) and, in UK (20%) [3]. In other countries such as France, Italy, this percentage exceeds 50% [3].

In line with our analysis, the results of recent systematic reviews [5,25,27,28] have documented the direct relationship between the level of severity of COPD, frequency of exacerbations and the direct costs. Advanced stages of COPD and exacerbations, lead to long lengths of stay in intensive care units, and in the emergency room and rise use of antibiotics, corticosteroids and oxygen therapy, which explains the increase in DHC as a function of severity and number of exacerbation. In addition, patients with advanced COPD may be treated with domiciliary (LTOT) or (NIV) [17], which leads to additional costs of care.

In the same direction, results of the BREATHE study [29], a large survey in the MENA region, including Morocco, have demonstrated that the use of all healthcare resources was significantly higher in subjects classified (C-D) than in those classified (A-B), and greater in those with exacerbations than in those without. According to the ARTIC study [30], patients with a high frequency of exacerbations have a high risk of future exacerbations, mortality and rapid decline in lung function and thus a significant economic burden.

COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. A study on the knowledge of Moroccan general practitioners on COPD [31] has shown insufficient management of this pathology by the general practitioner, who should normally be involved in the early diagnosis and management. This lack of knowledge can lead to a high percentage of cases being diagnosed late and, therefore, a high economic cost in our country.

Regarding smoking, the results showed a higher direct cost for smokers and ex-smokers compared to non-smokers. This result is in agreement with other studies [32,33] which show that tobacco smoking is associated with more use of health care resources and higher medical cost. Morocco is considered one of the largest consumers of tobacco, its prevalence is estimated at 13.4% [14], which will lead to an increase in the cost in our context. This results highlight the importance of smoking cessation; quit smoking improves symptoms and lung function in COPD patients, thus reducing costs [34].

This study allowed us to estimate the cost of COPD management and its determinants in Morocco using a bottom up approach. However, it has some limitations: first, it was conducted in a tertiary center, where most cases are in advanced stages, which may overestimate the cost. Second, intangible, and direct non-medical costs could not be

estimated due to the retrospective data collection, which can underestimate the cost of this disease.

In conclusion, the results of the present study show that the management of COPD in Morocco is associated with a significant economic burden. Direct costs for the COPD population were mainly represented by costs associated with hospitalizations as well as drug costs. This cost was related to the frequency of severe exacerbations, the severity of COPD and smoking.

### ***Recommendations***

These conclusions highlight the importance of prevention, the detection of disease in its early stages, and the control of frequency of the exacerbations in reducing the cost of disease. To prevent the disease and reduce its prevalence, it is necessary to fight its risk factors, especially tobacco, by educating people about the adverse effects of smoking and strengthening the legislative and regulatory aspects of tobacco control, especially by ratifying the WHO Framework Convention on Tobacco Control (WHO FCTC) signed in our country since 2004.

Regarding early detection, it requires to train primary health care facilities personnel as well as private general practitioners to improve their knowledge of symptoms and management of the disease. It's also necessary to organize screening campaigns. In addition, to control exacerbations and limit hospitalization, patients with COPD should benefit from education sessions, to better understand their disease and the interest of therapeutic compliance. Finally, it should be noted that more research is needed on this topic, especially for the measurement of indirect cost, so that we can conclude with more reliable estimates and compare the results with international studies.

## References

1. Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. *BMJ* 2022;378:e069679.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1204-22.
3. Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. *PLoS One* 2016;11:e0152618.
4. CDC. COPD costs. 2019. Available from: <https://www.cdc.gov/copd/infographics/copd-costs.html>. Accessed on: 16/07/2022.
5. Iheanacho I, Zhang S, King D, et al. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. *Int J Chron Obstruct Pulmon Dis* 2020;15:439-60.
6. Fishman PA, Khan ZM, Thompson EE, Curry SJ. Health care costs among smokers, former smokers, and never smokers in an HMO. *Health Serv Res* 2003;38:733-49.
7. Robbins AS, Fonseca VP, Chao SY, et al. Short term effects of cigarette smoking on hospitalisation and associated lost workdays in a young healthy population. *Tob Control* 2000;9:389-96.
8. Wacker M, Holle R, Heinrich J, et al. The association of smoking status with healthcare utilisation, productivity loss and resulting costs: results from the population-based KORA F4 study. *BMC Health Serv Res* 2013;13:278.
9. Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. *Int J Tuberc Lung Dis* 2019;23:1131-41.
10. Rossaki FM, Hurst JR, van Gemert F, et al. Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. *Expert Rev Respir Med* 2021;15:1563-77.
11. WHO. Chronic obstructive pulmonary disease (COPD). 2023. Available from: [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)). Accessed on: 23/05/2022.

12. Tageldin MA, Nafti S, Khan JA, et al. Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. *Respir Med* 2012;106:S25-32.
13. Rhazi KE, Nejari C, Benjelloun MC, et al. Prevalence of chronic obstructive pulmonary disease in Fez, Morocco: results from the BOLD study. *Int J Tuberc Lung Dis* 2016;20:136-41.
14. Ministry of Health. Rapport de l'enquête nationale sur les facteurs de risque des maladies non transmissibles 2017-2018. Available from: <https://www.sante.gov.ma/Documents/2019/05/Rapport%20de%20l%20enqu%C3%AAte%20Stepwise.pdf>.
15. Brakema EA, Tabyshova A, van der Kleij RMJJ, et al. The socioeconomic burden of chronic lung disease in low-resource settings across the globe – an observational FRESH AIR study. *Respir Res* 2019;20:291.
16. Jo C. Cost-of-illness studies: concepts, scopes, and methods. *Clin Mol Hepatol* 2014;20:327-37.
17. Global Initiative for Chronic Obstructive Lung Disease. Global strategy of the diagnosis, the management and prevention of obstructive pulmonary disease. 2018 report . Available from: [https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov\\_WMS.pdf](https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf)
18. Byford S, Torgerson DJ, Raftery J. Cost of illness studies. *BMJ* 2000;320:1335.
19. ANAM. Tarification nationale de référence . Available from: <https://anam.ma/anam/regulation/tarification-nationale-de-reference/>. [Material in French].
20. ANAM. Tarifs nationaux de référence pour le remboursement ou la prise en charge des appareillages et dispositifs médicaux. 2008. Available from: <https://www.cnss.ma/sites/default/files/Remboursement%20et%20prise%20en%20charge%20et%20appareillage%20des%20dispositifs%20m%C3%A9dicaux.pdf>
21. Ministry of Health. Assurance maladie obligatoire, guide des médicaments remboursables. Available from: <https://www.sante.gov.ma/Documents/Activite/guide%20mdcts%20remboursables.pdf>.

22. Invensting.com. USD MAD données historiques. Available from: <https://fr.investing.com/currencies/usd-mad-historical-data>. Accessed on: 18/07/2022.
23. WHO. Economics of tobacco toolkit: assessment of the economic costs of smoking. Available from: [https://iris.who.int/bitstream/handle/10665/44596/9789241501576\\_eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/44596/9789241501576_eng.pdf?sequence=1). Accessed on: 23/11/2023.
24. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. *Pharmacoeconomics* 1996;10:460-6.
25. Rehman AU, Hassali MAA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. *Expert Rev Pharmacoecon Outcomes Res* 2020;20:661-72.
26. Merino M, Villoro R, Hidalgo-Vega Á, Carmona C. Social economic costs of COPD in Extremadura (Spain): an observational study. *Int J Chron Obstruct Pulmon Dis* 2018;13:2501-14.
27. Rehman AU, Hassali MAA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. *Eur J Health Econ* 2020;21:181-94.
28. Gutiérrez Villegas C, Paz-Zulueta M, Herrero-Montes M, et al. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. *Health Econ Rev* 2021;11:31.
29. Idrees M, Koniski ML, Taright S, et al. Management of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. *Respir Med* 2012;106:S33-44.
30. Larsson K, Janson C, Lisspers K, et al. The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the ARCTIC study. *Int J Chron Obstruct Pulmon Dis* 2021;16:701-13.
31. Benouhoud N, Trombati N, Afif H, Aichane A, Bouayad Z. Evaluation de la prise en charge des broncho-pneumopathies chroniques obstructives auprès des médecins généralistes marocains du secteur libéral. *Revue de Pneumologie Clinique* 2007;63:40-4. [Article in French].

32. Ye BZ, Wang XY, Wang YF, et al. Impact of tobacco smoking on health care utilization and medical costs in chronic obstructive pulmonary disease, coronary heart disease and diabetes. *Curr Med Sci* 2022;42:304-16.
33. Örnek T, Tor M, Altın R, et al. Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. *Int J Med Sci* 2012;9:285-90.
34. Pezzuto A, Ricci A, D'Ascanio M, et al. Short-term benefits of smoking cessation improve respiratory function and metabolism in smokers. *Int J Chron Obstruct Pulmon Dis* 2023;18:2861-5.



**Table 1. Demographic and clinical characteristics of COPD patients (n=159).**

<b>Characteristics</b>	<b>Results n (%)</b>
<b>Age (means(SD))</b>	68.7(9.7)
<b>Gender (n=159)</b>	
Female	28(17.6)
Male	131(82.4)
<b>Working status (n=113)</b>	
Retired	20(17.7)
Employed	56(49.6)
Unemployed	37(32.7)
<b>Medical insurance (n=128)</b>	
RAMED	97(75.8)
Medical insurance	31(24.2)
<b>Smoking habits (n=158)</b>	
Ex-smoker/current smoker	127(80.4)
Non smoker	31(19.6)
<b>Exposure to household smoke (n=158)</b>	
Yes	25(15.8)
No	133(84.2)
<b>Years of COPD (means(SD))</b>	6,09(2.92)
<b>Frequency of severe exacerbation (n=159)</b>	
0 per year	94 (59.1)
≥1 per year	65 (40.9)
<b>Gold classification (n=155)</b>	
A-B	33(21.3)
C-D	122(78.7)

SD, standard deviation; %, percentage; RAMED, medical assistance scheme.

**Table 2. Utilization of health care resources at 2019 (n=159).**

<b>Resources typology</b>	<b>mean±SD / n (%)</b>
<b>Medical tests</b>	
Arterial gas-analysis	1.45±1.45
Spirometry	2.21±2.06
Walk test	1.52±1.36
Chest X ray	1.32±1.66
Tomography	0.44±0.69
<b>Pneumology visit</b>	3.7±1.7
<b>Hospitalization admission</b>	0.7±1.15
<b>Number of day in hospital</b>	13.01±11.48
<b>vaccination</b>	
Flu	44(27.7)
Pneumococcal	16(10.1)
<b>Use of home oxygen therapy</b>	32(20.1)
<b>Use of noninvasive home ventilation</b>	9(5.7)

SD, standard deviation; %, percentage.

**Table 3. Description of direct health cost per patient in dollars.**

<b>Direct cost categories</b>	<b>Total mean direct cost per patient(SD)</b>	<b>Percentage of direct cost</b>
<b>Medications</b>	773.3(470.7)	42.5
<b>Hospital admissions</b>	402(807.0)	22.1
<b>Medical tests</b>	278.6(201.4)	15.4
<b>Medical visits</b>	30.5(14.2)	1.7
<b>Vaccination</b>	10.6(28.2)	0.6
<b>Home oxygen therapy/home noninvasive ventilation</b>	321.3(630.3)	17.7
<b>Direct health cost</b>	1816.6(1582.7)	100

SD, standard deviation.

**Table 4. Factors associated with direct and indirect cost in COPD patients.**

	<b>Direct cost (mean(SD))</b>	<b>p-value</b>	<b>Indirect cost (mean(SD))</b>	<b>p-value</b>
<b>Smoking status</b>		<b>0.029</b>		<b>0.21</b>
Non smokers	1306.1(1093.6)		<b>544.9(915.0)</b>	
Former and current smokers	1944.4(1587.3)		<b>800.9(1169.8)</b>	
<b>COPD severity</b>		<b>&lt;0.001</b>		<b>0.87</b>
GOLD A-B	791.7(522.8)		<b>210.4(65.2)</b>	
GOLD C-D	2080.6(1618.6)		<b>886.6(1213.6)</b>	
<b>Frequency of severe exacerbations</b>		<b>&lt;0.001</b>		<b>0.003</b>
0	1009.8(620.3)		<b>473.9(862.7)</b>	
≥1	2983.4(1812.8)		<b>1181.5(1334.8)</b>	